Glypican1: A potential cancer biomarker for nanotargeted therapy

dc.contributor.author	Tripathi A.D.; Katiyar S.; Mishra A.
dc.date.accessioned	2025-05-23T11:16:47Z
dc.description.abstract	Glypicans (GPCs) are generally involved in cellular signaling, growth and proliferation. Previous studies reported their roles in cancer proliferation. GPC1 is a co-receptor for a variety of growth-related ligands, thereby stimulating the tumor microenvironment by promoting angiogenesis and epithelial–mesenchymal transition (EMT). This work reviews GPC1-biomarker-assisted drug discovery by the application of nanostructured materials, creating nanotheragnostics for targeted delivery and application in liquid biopsies. The review includes details of GPC1 as a potential biomarker in cancer progression as well as a potential candidate for nano-mediated drug discovery. © 2023 Elsevier Ltd
dc.identifier.doi	https://doi.org/10.1016/j.drudis.2023.103660
dc.identifier.uri	http://172.23.0.11:4000/handle/123456789/6668
dc.relation.ispartofseries	Drug Discovery Today
dc.title	Glypican1: A potential cancer biomarker for nanotargeted therapy

Collections